A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
457
Enrollment
INDUSTRY
Sponsor class

Stopped Study was terminated during Open Label Extension period because analyses of placebo-controlled Blinded portion of study did not show any evidence of clinical efficacy or modulation of accumulation of tau PET signal at any of the doses studied.

Conditions

Interventions

Sponsor

Genentech, Inc.